US2020390855A1PendingUtilityA1

Compositions, articles of manufacture and methods for treating cancer

76
Assignee: BIOKINE THERAPEUTICS LTDPriority: Jul 16, 2015Filed: Aug 31, 2020Published: Dec 17, 2020
Est. expiryJul 16, 2035(~9 yrs left)· nominal 20-yr term from priority
Inventors:Amnon PeledYaron Pereg
A61K 2039/55522A61P 35/00A61K 47/646A61K 39/12A61K 45/06A61K 38/395A61K 38/04C07K 16/2818C07K 16/2827A61K 39/3955A61K 38/10C07K 2317/76A61K 38/1761C07K 16/30A61K 2300/00A61K 39/395
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and an anti-cancer agent, thereby treating the cancer in the subject.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An article of manufacture identified for use in treating cancer, comprising a packaging material, packaging a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 and an immune checkpoint regulator, wherein said immune checkpoint regulator is selected from the group consisting of B7H2, B7H3, B7H4, BTLA-4, HVEM, CD80, CD86, CD19, OX40L, 4-1BBL, CD70, CD40L, ICOSL and VISTA. 
     
     
         2 . The article of manufacture of  claim 1 , wherein said peptide and said immune checkpoint regulator are in separate containers. 
     
     
         3 . The article of manufacture of  claim 1 , wherein said peptide and said immune checkpoint regulator are in a co-formulation. 
     
     
         4 . The article of manufacture of  claim 1 , wherein said cancer is a non-solid tumor. 
     
     
         5 . The article of manufacture of  claim 1 , wherein said cancer is a solid tumor. 
     
     
         6 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 and an immune checkpoint regulator, wherein said immune checkpoint regulator is selected from the group consisting of B7H2, B7H3, B7H4, BTLA-4, HVEM, CD80, CD86, CD19, OX40L, 4-1BBL, CD70, CD40L, ICOSL and VISTA. 
     
     
         7 . The method of  claim 6 , wherein said peptide and said immune checkpoint regulator are in separate containers. 
     
     
         8 . The method of  claim 6 , wherein said peptide and said immune checkpoint regulator are in a co-formulation. 
     
     
         9 . The method of  claim 6 , wherein said cancer is a non-solid tumor. 
     
     
         10 . The method of  claim 6 , wherein said cancer is a solid tumor.

Join the waitlist — get patent alerts

Track US2020390855A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.